Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04447768
Recruitment Status : Recruiting
First Posted : June 25, 2020
Last Update Posted : August 5, 2021
Genentech, Inc.
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 2023
Estimated Study Completion Date : July 2023